VEGFA and COVID-19: These platforms have been employed in the development of plant-based vaccines against infectious diseases such as COVID-19 (Jung et al., 2022), and in the production of therapeutic proteins like recombinant anti-vascular endothelial growth factor (anti-VEGF) antibodies, which are used in angiogenesis inhibition and cancer therapy (Soleimanizadeh et al., 2022).Their short expression timeline also makes them suitable for gene editing applications, where fast prototyping and validation are essential (Zhang et al., 2020; Yao et al., 2020).